Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
Public ClinicalTrials.gov record NCT04662671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
Study identification
- NCT ID
- NCT04662671
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 31 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2020
- Primary completion
- Dec 8, 2020
- Completion
- Jan 29, 2021
- Last update posted
- Sep 7, 2022
2020 – 2021
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 2 | Miami | Florida | 33134 | — |
| Site 1 | College Station | Texas | 77845 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated COVID19 trials
Other public records listing COVID19. Sorted by last update posted; newest first. Not a recommendation.
- NCT04652115: Defibrotide for the Treatment of Severe COVID-19 Recruiting
- NCT03305341: Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix Active, not recruiting
- NCT04956445: Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development Recruiting
- NCT04815096: Imaging Immune Activation in COVID-19 Recruiting
- NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin Recruiting
- NCT04896606: SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04662671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2022 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04662671 live on ClinicalTrials.gov.